Table 2 Methylation levels in breast cancer subtypes

CD40

24.3 ± 12.3 (21.7)

30.8 ± 11.9 (36.2)

30.8 ± 11.9 (33.4)

27.4 ± 7.9 (23.9)

<0.001

DBC1

12.8 ± 9.2 (15.9)

19.9 ± 10.3 (34.1)

17.8 ± 8.2 (42.7)

14.0 ± 7.3 (19.5)

<0.001

FGF2

7.4 ± 7.2 (11.1)

23.1 ± 11.2 (63.8)

32.2 ± 13.9 (67.5)

15.0 ± 13.4 (30.8)

<0.001

HOXA9

21.1 ± 12.0 (61.8)

22.5 ± 9.4 (64.7)

28.4 ± 10.3 (83.8)

20.3 ± 8.0 (78.1)

NS

HS3ST2

10.3 ± 11.9 (31.0)

23.9 ± 12.9 (75.0)

26.8 ± 12.3 (79.8)

17.5 ± 13.2 (40.4)

<0.001

JAK 3

28.0 ± 15.3 (53.5)

36.8 ± 15.2 (87.5)

33.3 ± 13.7 (74.1)

28.8 ± 10.3 (83.0)

<0.001

Let-7a

33.9 ± 11.3 (19.1)

55.1 ± 10.9 (72.9)

48.8 ± 15.7 (65.7)

53.5 ± 8.4 (80.0)

<0.001

LINE-1

63.8 ± 3.2 (30.2)

63.1 ± 6.2 (40.4)

63.8 ± 7.8 (40.2)

62.8 ± 4.7 (30.4)

NS

Mir-10a

15.5 ± 4.2 (36.4)

25.2 ± 5.8 (70.8)

23.1 ± 10.1 (77.4)

20.8 ± 11.3 (63.2)

<0.001

Mir-93 a

55.6 ± 7.3 (23.9)

60.6 ± 6.5 (57.8)

61.2 ± 8.9 (62.1)

61.3 ± 6.5 (47.5)

<0.001

NPY

14.9 ± 4.9 (35.6)

38.9 ± 14.6 (95.8)

34.5 ± 14.5 (80.9)

27.4 ± 14.8 (78.6)

<0.001

PRKCDBP

7.6 ± 6.1 (4.3)

13.2 ± 10.0 (12.5)

15.6 ± 10.1 (22.3)

10.6 ± 8.4 (15.0)

<0.001

RASSF1

20.4 ± 11.9 (35.7)

33.9 ± 12.9 (79.2)

35.6 ± 10.8 (74.5)

23.5 ± 5.9 (73.9)

<0.001

SOX 1

19.8 ± 10.7 (75.0)

24.5 ± 11.2 (81.3)

21.5 ± 10.1 (78.6)

20.7 ± 10.1 (53.3)

<0.001

SOX17

19.1 ± 15.6 (59.1)

22.4 ± 14.2 (70.8)

23.2 ± 14.7 (62.4)

14.1 ± 7.2 (32.4)

<0.001

SPARC

35.3 ± 10.7 (48.9)

33.7 ± 10.2 (60.4)

34.5 ± 12.2 (67.3)

31.1 ± 11.0 (68.1)

NS

TAL1

38.8 ± 12.5 (59.1)

33.9 ± 11.3 (56.5)

37.7 ± 11.6 (60.4)

27.4 ± 7.9 (52.3)

NS

TNFRS10D

12.5 ± 12.6 (27.8)

18.9 ± 8.8 (60.9)

23.5 ± 11.3 (65.7)

19.6 ± 9.2 (60.0)

<0.001

VAMP8

8.8 ± 3.8 (93.1)

12.4 ± 4.4 (72.1)

11.4 ± 3.9 (77.2)

11.9 ± 4.1 (79.2)

<0.001